FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.
What happened
FDA inspected RNA Bio/Pharma’s drug manufacturing facility in Chelan, WA, from April 9 to April 11, 2025, and cited significant CGMP (current good manufacturing practice) violations for finished drugs. FDA said the firm did not test incoming components such as glycerin and ethanol, relied on supplier certificates without validating them, and did not adequately validate or monitor its water system. The firm also had not responded to FDA’s Form FDA 483 (inspection observations) despite two FDA inquiries.
What FDA found
The firm did not test each incoming component for purity, strength, and quality and did not validate its suppliers’ test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not test high-risk glycerin for diethylene glycol or ethylene glycol identity before use.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm relied on supplier certificates for ethanol without adequately testing for methanol or benzene.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not perform identity, purity, strength, or quality testing on other components, including mother tinctures and a highly toxic ingredient used as a rodenticide.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm’s water system was under a sink, did not continuously circulate, and was not validated or monitored for chemical and microbial quality.
21 CFR 211.100(a)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with corrective actions, including diethylene glycol and ethylene glycol test results within 30 calendar days and risk assessments for affected products, components, and water.
Who should pay attention
- brands or retailers selling homeopathic oral liquids
- makers and buyers of glycerin or ethanol drug components
- quality teams responsible for pharmaceutical water systems
This is a summary. Read the original letter on fda.gov.